An Open-label, Multicenter, Phase Ib Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects Aged 2 to 17 Years With Atopic Dermatitis
Latest Information Update: 07 Aug 2024
At a glance
- Drugs B 244 (Primary)
- Indications Atopic dermatitis; Eczema
- Focus Adverse reactions
- Sponsors AOBiome
Most Recent Events
- 29 Jun 2020 Results presented in an AOBiome media release.
- 19 Aug 2019 Status changed from active, no longer recruiting to completed.
- 11 Jun 2019 Status changed from recruiting to active, no longer recruiting.